CL2019001804A1 - Activador de nrf2. - Google Patents
Activador de nrf2.Info
- Publication number
- CL2019001804A1 CL2019001804A1 CL2019001804A CL2019001804A CL2019001804A1 CL 2019001804 A1 CL2019001804 A1 CL 2019001804A1 CL 2019001804 A CL2019001804 A CL 2019001804A CL 2019001804 A CL2019001804 A CL 2019001804A CL 2019001804 A1 CL2019001804 A1 CL 2019001804A1
- Authority
- CL
- Chile
- Prior art keywords
- nrf2 activator
- nrf2
- activator
- compounds
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/76—Benzo[c]pyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
SE PROPORCIONAN COMPUESTOS DE FÓRMULA I, O LAS SALES FARMACÉUTICAMENTE ACEPTABLES DE ESTOS, Y MÉTODOS PARA SU USO Y PRODUCCIÓN.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662439289P | 2016-12-27 | 2016-12-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2019001804A1 true CL2019001804A1 (es) | 2019-11-15 |
Family
ID=61007836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019001804A CL2019001804A1 (es) | 2016-12-27 | 2019-06-27 | Activador de nrf2. |
Country Status (21)
Country | Link |
---|---|
US (2) | US10968181B2 (es) |
EP (2) | EP3562816B1 (es) |
JP (1) | JP7088933B2 (es) |
KR (1) | KR20190111949A (es) |
CN (1) | CN110382475A (es) |
AR (1) | AR110590A1 (es) |
AU (1) | AU2017387070B2 (es) |
BR (1) | BR112019013341A2 (es) |
CA (1) | CA3048849A1 (es) |
CL (1) | CL2019001804A1 (es) |
CO (1) | CO2019008110A2 (es) |
CR (1) | CR20190344A (es) |
EA (1) | EA201991595A1 (es) |
ES (1) | ES2878102T3 (es) |
IL (1) | IL267692B (es) |
JO (1) | JOP20190163B1 (es) |
MX (1) | MX2019007826A (es) |
PE (1) | PE20191488A1 (es) |
TW (1) | TW201827406A (es) |
UY (1) | UY37551A (es) |
WO (1) | WO2018125880A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2021006527A (es) | 2018-12-05 | 2021-07-21 | Scohia Pharma Inc | Compuesto macrociclico y su uso. |
CN112679328B (zh) * | 2019-10-17 | 2023-09-15 | 南京药石科技股份有限公司 | 一种3-三氟甲基-2-环己烯-1-酮的工业化生产方法 |
KR20230021505A (ko) | 2021-08-05 | 2023-02-14 | 주식회사 엘씨에스바이오텍 | 신규한 곡류 발효물, 그 곡류 발효물의 피부 보호 용도, 피부 유용 물질 스크리닝 방법 및 산화적 스트레스로 인한 피부 손상 예측 방법 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
JP2008110962A (ja) * | 2006-08-02 | 2008-05-15 | Santen Pharmaceut Co Ltd | Nrf2活性化物質を有効成分として含む角結膜障害の予防または治療剤 |
MX339476B (es) | 2008-04-18 | 2016-05-27 | Reata Pharmaceuticals Inc | Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso. |
US9139592B2 (en) * | 2010-06-14 | 2015-09-22 | Trt Pharma Inc. | Modulators of Nrf2 and uses thereof |
US20140088052A1 (en) * | 2011-02-25 | 2014-03-27 | The Johns Hopkins University | Chalcone derivatives as nrf2 activators |
US20170354639A1 (en) | 2014-10-24 | 2017-12-14 | Biogen Ma Inc. | Diterpenoid derivatives and methods of use thereof |
JP2018517732A (ja) * | 2015-06-15 | 2018-07-05 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Nrf2レギュレーター |
-
2017
- 2017-12-26 UY UY0001037551A patent/UY37551A/es unknown
- 2017-12-26 AR ARP170103684A patent/AR110590A1/es unknown
- 2017-12-27 TW TW106146033A patent/TW201827406A/zh unknown
- 2017-12-27 CN CN201780087398.9A patent/CN110382475A/zh active Pending
- 2017-12-27 KR KR1020197022052A patent/KR20190111949A/ko not_active Application Discontinuation
- 2017-12-27 EA EA201991595A patent/EA201991595A1/ru unknown
- 2017-12-27 CA CA3048849A patent/CA3048849A1/en active Pending
- 2017-12-27 JP JP2019535363A patent/JP7088933B2/ja active Active
- 2017-12-27 BR BR112019013341A patent/BR112019013341A2/pt active Search and Examination
- 2017-12-27 US US16/473,667 patent/US10968181B2/en active Active
- 2017-12-27 JO JOP/2019/0163A patent/JOP20190163B1/ar active
- 2017-12-27 WO PCT/US2017/068455 patent/WO2018125880A1/en active Application Filing
- 2017-12-27 AU AU2017387070A patent/AU2017387070B2/en active Active
- 2017-12-27 PE PE2019001341A patent/PE20191488A1/es unknown
- 2017-12-27 MX MX2019007826A patent/MX2019007826A/es unknown
- 2017-12-27 EP EP17832681.5A patent/EP3562816B1/en active Active
- 2017-12-27 EP EP21152411.1A patent/EP3875450A1/en active Pending
- 2017-12-27 CR CR20190344A patent/CR20190344A/es unknown
- 2017-12-27 ES ES17832681T patent/ES2878102T3/es active Active
-
2019
- 2019-06-27 CL CL2019001804A patent/CL2019001804A1/es unknown
- 2019-06-27 IL IL267692A patent/IL267692B/en unknown
- 2019-07-26 CO CONC2019/0008110A patent/CO2019008110A2/es unknown
-
2021
- 2021-04-02 US US17/221,358 patent/US20210340107A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JOP20190163A1 (ar) | 2019-06-27 |
CO2019008110A2 (es) | 2019-08-20 |
CR20190344A (es) | 2019-11-19 |
AU2017387070A1 (en) | 2019-08-15 |
WO2018125880A8 (en) | 2019-06-06 |
KR20190111949A (ko) | 2019-10-02 |
CA3048849A1 (en) | 2018-07-05 |
US20210340107A1 (en) | 2021-11-04 |
UY37551A (es) | 2018-07-31 |
EP3562816A1 (en) | 2019-11-06 |
EP3562816B1 (en) | 2021-01-20 |
AU2017387070B2 (en) | 2022-03-24 |
WO2018125880A1 (en) | 2018-07-05 |
CN110382475A (zh) | 2019-10-25 |
IL267692B (en) | 2021-09-30 |
EA201991595A1 (ru) | 2020-01-27 |
EP3875450A1 (en) | 2021-09-08 |
US20190345112A1 (en) | 2019-11-14 |
MX2019007826A (es) | 2019-10-24 |
ES2878102T3 (es) | 2021-11-18 |
TW201827406A (zh) | 2018-08-01 |
US10968181B2 (en) | 2021-04-06 |
JOP20190163B1 (ar) | 2023-09-17 |
JP7088933B2 (ja) | 2022-06-21 |
JP2020503332A (ja) | 2020-01-30 |
IL267692A (en) | 2019-08-29 |
AR110590A1 (es) | 2019-04-10 |
BR112019013341A2 (pt) | 2019-12-24 |
PE20191488A1 (es) | 2019-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019002734A1 (es) | Isoquinolinas como inhibidores de hpk1. | |
CO2020000527A2 (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp | |
CL2017000902A1 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
NI201700096A (es) | Derivados de 4h-pirrol[3, 2-c]piridin-4-ona | |
UY36564A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
CU20160149A7 (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4 | |
CU20180001A7 (es) | Derivados de oxopiridina sustituidos y procesos para su preparación | |
CL2017001923A1 (es) | Derivados de 9h-pirrolo-dipiridina | |
UY36175A (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
CL2016001973A1 (es) | Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza. | |
CL2017003107A1 (es) | Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak | |
AR102981A1 (es) | Inhibidores de la necrosis celular y métodos de preparación de los mismos | |
CR20170146A (es) | Formas cristalinas de 5-cloro-n4-[-2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-yl)piperidin-1-il]pirimidina-2,4-diamina | |
ECSP16074478A (es) | Compuestos novedosos | |
UY36737A (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
UY35274A (es) | Compuestos y métodos para tratar infecciones bacterianas | |
ECSP18074962A (es) | Derivados de aminotiazol útiles como agentes antivíricos | |
EA201790627A1 (ru) | СТИМУЛЯТОРЫ рГЦ | |
CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
UY36070A (es) | Triterpenoides con actividad inhibidora de la maduración de hiv | |
CL2017002689A1 (es) | Derivados de pirrolidincarboxamido y métodos para prepararlos y usarlos | |
DOP2018000066A (es) | Compuestos útiles para inhibir ror-gamma-t | |
DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
CL2016002089A1 (es) | Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
CL2019001804A1 (es) | Activador de nrf2. |